Wedbush raised the firm’s price target on Apellis to $60 from $39 and keeps a Neutral rating on the shares. The recent ASRS ReST publication does not necessarily identify a cause for the recent retinal vasculitis cases, but does validate that the rate remains low with no additional cases reported since September, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis price target raised to $77 from $73 at BofA
- Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
- Apellis reports preliminary FY23 SYFOVRE, EMPAVELI revenue of $366M
- Apellis reports preliminary Q4 SYFOVRE revenue of $138M
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
